IS8363A - Endurbætur á bólusetningum - Google Patents

Endurbætur á bólusetningum

Info

Publication number
IS8363A
IS8363A IS8363A IS8363A IS8363A IS 8363 A IS8363 A IS 8363A IS 8363 A IS8363 A IS 8363A IS 8363 A IS8363 A IS 8363A IS 8363 A IS8363 A IS 8363A
Authority
IS
Iceland
Prior art keywords
vaccination
vaccination improvements
Prior art date
Application number
IS8363A
Other languages
English (en)
Inventor
Peter Bembridge Gary
L. Craigen Jennifer
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of IS8363A publication Critical patent/IS8363A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
IS8363A 2003-09-15 2006-03-20 Endurbætur á bólusetningum IS8363A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0321615.7A GB0321615D0 (en) 2003-09-15 2003-09-15 Improvements in vaccination
PCT/EP2004/010322 WO2005025614A2 (en) 2003-09-15 2004-09-13 Improvements in vaccination

Publications (1)

Publication Number Publication Date
IS8363A true IS8363A (is) 2006-03-20

Family

ID=29227139

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8363A IS8363A (is) 2003-09-15 2006-03-20 Endurbætur á bólusetningum

Country Status (19)

Country Link
US (1) US20080145375A1 (is)
EP (1) EP1682175A2 (is)
JP (1) JP2007505827A (is)
KR (1) KR20070029111A (is)
CN (1) CN1878567A (is)
AU (1) AU2004271726A1 (is)
BR (1) BRPI0414381A (is)
CA (1) CA2538197A1 (is)
GB (1) GB0321615D0 (is)
IL (1) IL174131A0 (is)
IS (1) IS8363A (is)
MA (1) MA28323A1 (is)
MX (1) MXPA06002969A (is)
NO (1) NO20061242L (is)
NZ (1) NZ545948A (is)
RU (1) RU2370537C2 (is)
SG (1) SG145767A1 (is)
WO (1) WO2005025614A2 (is)
ZA (1) ZA200602156B (is)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
MXPA06001669A (es) 2003-08-12 2006-04-28 3M Innovative Properties Co Compuestos que contienen imidazo-oxima sustituidos.
NZ545412A (en) 2003-08-27 2008-12-24 Coley Pharm Group Inc Aryloxy and arylalkyleneoxy substituted imidazoquinolines
JP2007504269A (ja) 2003-09-05 2007-03-01 スリーエム イノベイティブ プロパティズ カンパニー Ｃｄ５＋ｂ細胞リンパ腫の治療方法
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
EP1673087B1 (en) 2003-10-03 2015-05-13 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
WO2005048933A2 (en) 2003-11-14 2005-06-02 3M Innovative Properties Company Oxime substituted imidazo ring compounds
CN1906192A (zh) 2003-11-14 2007-01-31 3M创新有限公司 羟胺取代的咪唑环化合物
AU2004293078B2 (en) 2003-11-25 2012-01-19 3M Innovative Properties Company Substituted imidazo ring systems and methods
FR2863890B1 (fr) * 2003-12-19 2006-03-24 Aventis Pasteur Composition immunostimulante
JP2007517035A (ja) 2003-12-29 2007-06-28 スリーエム イノベイティブ プロパティズ カンパニー アリールアルケニルおよびアリールアルキニル置換されたイミダゾキノリン
EP1699398A4 (en) * 2003-12-30 2007-10-17 3M Innovative Properties Co IMPROVING THE IMMUNE RESPONSE
EP1699788A2 (en) 2003-12-30 2006-09-13 3M Innovative Properties Company Imidazoquinolinyl, imidazopyridinyl and imidazonaphthyridinyl sulfonamides
US8697873B2 (en) 2004-03-24 2014-04-15 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
WO2005107381A2 (en) 2004-05-07 2005-11-17 Hans-Gustaf Ljunggren Use of flagellin as an adjuvant for vaccine
US8017779B2 (en) 2004-06-15 2011-09-13 3M Innovative Properties Company Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
WO2006038923A2 (en) 2004-06-18 2006-04-13 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
US7915281B2 (en) 2004-06-18 2011-03-29 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
WO2006009826A1 (en) 2004-06-18 2006-01-26 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
CA2592904C (en) 2004-12-30 2015-04-07 3M Innovative Properties Company Chiral fused [1,2]imidazo[4,5-c] ring compounds
JP5313502B2 (ja) 2004-12-30 2013-10-09 スリーエム イノベイティブ プロパティズ カンパニー 置換キラル縮合［１，２］イミダゾ［４，５−ｃ］環状化合物
JP2008530022A (ja) 2005-02-04 2008-08-07 コーリー ファーマシューティカル グループ，インコーポレイテッド 免疫反応調節物質を含む水性ゲル処方物
EP1846405A2 (en) 2005-02-11 2007-10-24 3M Innovative Properties Company Oxime and hydroxylamine substituted imidazo 4,5-c ring compounds and methods
CA2602590A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
CA2602683A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. Pyrazolopyridine-1,4-diamines and analogs thereof
EP1909564A4 (en) 2005-07-18 2010-06-30 Novartis Ag SMALL ANIMAL MODEL FOR HCV REPLICATION
CN101340931A (zh) * 2005-09-27 2009-01-07 科利制药公司 使用连接寡核苷酸调节tlr介导的免疫应答
WO2007042169A2 (en) 2005-10-07 2007-04-19 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Matrix metalloproteinase 11 vaccine
CA2523032A1 (en) 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
DK2347775T3 (da) 2005-12-13 2020-07-13 Harvard College Skabeloner til celletransplantation
CN103122360A (zh) 2006-02-28 2013-05-29 瓦克萨特公司 嵌合腺病毒载体
WO2007109813A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
EP2589654A1 (en) 2006-05-03 2013-05-08 The Regents of the University of Colorado, a body corporate CD40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
JP5427027B2 (ja) * 2006-05-03 2014-02-26 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・コロラド，ア・ボディー・コーポレイト Ｃｄ４０アゴニスト抗体／ｉ型インターフェロン相乗性アジュバントの結合体、それを含む複合体、および細胞性免疫を強化する治療としてのその使用
WO2008008432A2 (en) 2006-07-12 2008-01-17 Coley Pharmaceutical Group, Inc. Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods
CA2657353A1 (en) 2006-07-18 2008-01-24 Glaxosmithkline Biologicals S.A. Vaccines for malaria
GB0617387D0 (en) * 2006-09-04 2006-10-11 Glaxo Group Ltd Synthetic gene
CA2679410C (en) 2007-03-02 2017-01-17 Glaxosmithkline Biologicals S.A. Novel method and compositions
DE102007044093A1 (de) * 2007-09-14 2009-03-19 Phenion Gmbh & Co. Kg Nukleinsäurehaltige kosmetische und/oder pharmazeutische Zubereitungen zur Induktion antimikrobieller Peptide in epithelialen Deckgeweben
JP5731198B2 (ja) 2007-09-27 2015-06-10 イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． インビボでのポリヌクレオチドの送達のための連続疎水相を含む担体におけるリポソームの使用
WO2009059328A2 (en) * 2007-11-02 2009-05-07 The Johns Hopkins University Multi- component l2 vaccine for prevention of human papillomavirus infection
KR100900837B1 (ko) * 2007-12-07 2009-06-04 (주)두비엘 리포펩타이드와 폴리(ｉ:ｃ)를 아쥬반트로 포함하는 강력한백신 조성물
CN102006891B (zh) 2008-02-13 2017-04-26 哈佛学院董事会 连续的细胞程序化装置
JP5190628B2 (ja) * 2008-03-31 2013-04-24 一般財団法人阪大微生物病研究会 混合免疫賦活剤を含む新規ワクチン
US8410258B2 (en) 2008-05-21 2013-04-02 Infections Disease Research Institute Recombinant polyprotein vaccines for the treatment and diagnosis of leishmaniasis
US8425919B2 (en) 2008-05-21 2013-04-23 Infectious Disease Research Institute Recombinant polyprotein vaccines for the treatment and diagnosis of leishmaniasis
CN102056622B (zh) 2008-06-05 2016-04-06 免疫疫苗技术有限公司 包含脂质体、抗原、多核苷酸和含疏水物质的连续相的载体的组合物
US20100160368A1 (en) * 2008-08-18 2010-06-24 Gregory Jefferson J Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy
BRPI0919245A2 (pt) * 2008-09-24 2021-11-03 Us Gov Sec Army Vacina para malária
AU2009323996A1 (en) * 2008-12-03 2011-07-07 Institut Pasteur Use of phenol-soluble modulins for vaccine development
WO2010067262A1 (en) 2008-12-09 2010-06-17 Pfizer Inc. Immunostimulatory oligonucleotides
CN102458463B (zh) 2009-05-22 2017-01-18 健诺西生物科学公司 针对ⅱ型单纯疱疹病毒的疫苗：诱发免疫应答的组合物和方法
CN102482666B (zh) 2009-07-06 2017-02-08 变异生物技术公司 制备囊泡的方法和由其产生的制剂
CA2803282C (en) * 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
MX336923B (es) 2009-07-13 2016-02-05 Medicis Pharmaceutical Corp Formulaciones de imiquimod de concentracion de dosificacion inferior y regimenes de dosificacion cortos para tratar verrugas genitales y perianales.
US20110077263A1 (en) * 2009-09-29 2011-03-31 University Of Southern California Methods and Compositions of Toll-Like Receptor (TLR) Agonists
BR112012027745A2 (pt) * 2010-04-27 2017-01-10 Univ Johns Hopkins método e composição imunogênica para tratamento de neoplásia
CN103096922B (zh) 2010-07-06 2019-08-06 变异生物技术公司 用于治疗流行性感冒的组合物和方法
LT2606047T (lt) * 2010-08-17 2017-04-10 3M Innovative Properties Company Imuninio atsako modifikatoriaus junginio lipidizuotos kompozicijos, sudėtys ir būdai
WO2012040101A1 (en) 2010-09-21 2012-03-29 University Of Miami Compositions and methods for inducing migration by dendritic cells and an immune response
EP3620185A1 (en) 2010-10-06 2020-03-11 President and Fellows of Harvard College Injectable, pore-forming hydrogels for materials-based cell therapies
CA2856697A1 (en) 2010-11-24 2012-06-07 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
FR2969657B1 (fr) 2010-12-22 2014-02-07 Fabre Pierre Dermo Cosmetique Nouvelle bacterie et extraits de ladite bacterie et leur utilisation en dermatologie
FR2969658B1 (fr) 2010-12-22 2014-10-17 Fabre Pierre Dermo Cosmetique Nouvelle bacterie et extraits de ladite bacterie et leur utilisation therapeutique
BR112013017939B1 (pt) 2011-01-13 2022-11-16 Variation Biotechnologies Inc Composição imunogênica liofilizada termoestável, uso e método para preparação da mesma
WO2012113413A1 (en) 2011-02-21 2012-08-30 Curevac Gmbh Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
RU2642300C2 (ru) 2011-08-17 2018-01-24 Глоубиммьюн, Инк. Иммунотерапевтические композиции на основе дрожжей-muc1 и способы их применения
CA2849259A1 (en) * 2011-09-19 2013-03-28 The Johns Hopkins University Cancer immunotherapy
CN113876945A (zh) 2011-10-06 2022-01-04 免疫疫苗技术有限公司 包括激活或增加tlr2活性的佐剂的脂质体组合物及其应用
JP6199878B2 (ja) 2011-11-23 2017-09-20 ジェノセア バイオサイエンシーズ， インコーポレイテッド 単純ヘルペスウイルス２型に対する核酸ワクチン：免疫応答を誘発する組成物及び方法
EP2802353A4 (en) 2012-01-12 2015-12-02 Variation Biotechnologies Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS
CN104244984B (zh) 2012-01-27 2020-03-31 变异生物技术公司 用于治疗剂的方法和组合物
PT2838515T (pt) 2012-04-16 2020-02-25 Harvard College Composições de sílica mesoporosa para modular respostas imunológicas
KR101501583B1 (ko) * 2013-03-29 2015-03-12 주식회사 차백신연구소 리포펩티드 및 폴리(ｉ:ｃ)를 포함하는 아쥬반트 및 이를 이용한 개선된 제형의 백신 조성물
WO2014163213A1 (en) * 2013-04-05 2014-10-09 Kyushu University, National University Corporation Anti-tumor dna vaccine
CA2915728A1 (en) 2013-08-21 2015-02-26 Thomas Kramps Respiratory syncytial virus (rsv) vaccine
HUE043042T2 (hu) * 2013-11-01 2019-07-29 Pfizer Vektorok prosztatához kapcsolódó antigének expressziójára
WO2015092710A1 (en) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Contralateral co-administration of vaccines
EP3137105A4 (en) 2014-04-30 2017-12-27 President and Fellows of Harvard College Combination vaccine devices and methods of killing cancer cells
HK1247861A1 (zh) 2015-01-30 2018-10-05 President And Fellows Of Harvard College 用於癌症治疗的肿瘤周围和肿瘤内部材料
CN114099793A (zh) 2015-04-10 2022-03-01 哈佛学院院长等 免疫细胞捕获装置及其制备和使用方法
JP6534146B2 (ja) * 2015-06-10 2019-06-26 国立大学法人 東京大学 ワクチン用アジュバント、ワクチン、及び免疫誘導方法
CN105031646A (zh) * 2015-07-16 2015-11-11 一达国际生物科技(北京)有限公司 抗肿瘤疫苗佐剂、其制备方法和编码核酸以及抗肿瘤疫苗组合物
US10925950B2 (en) 2015-08-03 2021-02-23 University Of Washington Immunogenic compositions, antigen screening methods, and methods of generating immune responses
CN115487351A (zh) 2016-02-06 2022-12-20 哈佛学院校长同事会 重塑造血巢以重建免疫
EP3484448B1 (en) 2016-07-13 2025-04-09 President and Fellows of Harvard College Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
RU2770060C2 (ru) 2016-08-02 2022-04-14 Президент Энд Феллоуз Оф Гарвард Колледж Биологические материалы для модуляции иммунных ответов
US10350288B2 (en) 2016-09-28 2019-07-16 Genocea Biosciences, Inc. Methods and compositions for treating herpes
WO2020061129A1 (en) 2018-09-19 2020-03-26 President And Fellows Of Harvard College Compositions and methods for labeling and modulation of cells in vitro and in vivo
EP4034148A4 (en) 2019-09-23 2025-09-10 Harvard College BIOMATERIAL-BASED ANTIGEN-FREE VACCINE AND ITS USE
CA3173603A1 (en) * 2020-05-14 2021-11-18 Yen-Ta Lu Selective targeting of the treml1/md2 interaction by small peptide or protein and its use for vaccine adjuvants
CN114377122B (zh) * 2022-01-18 2023-04-07 四川大学 一种基于四面体框架核酸的复合佐剂、mRNA疫苗及其制备方法和用途
CN115819617A (zh) * 2022-08-19 2023-03-21 辽宁成大生物股份有限公司 一种水痘-带状疱疹病毒重组嵌合蛋白及其编码基因、重组质粒载体、转化体和疫苗

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5697901A (en) 1989-12-14 1997-12-16 Elof Eriksson Gene delivery by microneedle injection
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
ZA929870B (en) 1991-12-23 1993-08-18 Duphar Int Res Adjuvants
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
SG48309A1 (en) 1993-03-23 1998-04-17 Smithkline Beecham Biolog Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
JP3967769B2 (ja) 1993-11-17 2007-08-29 オーエム・ファルマ グルコサミンジサッカライド、それらの製造法、それらを含む医薬組成物およびそれらの使用
EP1293559B1 (en) 1994-01-21 2005-07-27 Powderject Vaccines, Inc. Gas driven gene delivery instrument
CA2280195A1 (en) 1997-02-07 1998-08-13 Merck & Co., Inc. Synthetic hiv gag genes
ES2227825T3 (es) 1997-04-01 2005-04-01 Corixa Corporation Composiciones inmunologicas aduvantes acuosas de monofosforil lipido a.
US6130043A (en) * 1997-05-02 2000-10-10 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
ATE513042T1 (de) 1998-02-05 2011-07-15 Glaxosmithkline Biolog Sa Tumorassoziierte antigenderivate der mage-familie,nukleinsäuresequenzen, die dafür kodieren, zur herstellung von fusionsproteinen und zusammensetzungen zur impfung
TR200003225T2 (tr) * 1998-03-02 2001-02-21 Applied Vaccine Technologies Copr. Bağışıklık tepkisini modüle etmek için yöntemler ve araçlar
KR100797876B1 (ko) 1998-04-07 2008-01-24 코릭사 코포레이션 마이코박테리움 튜베르쿨로시스 항원의 융합 단백질 및이의 용도
AU780109B2 (en) 1999-01-29 2005-03-03 Corixa Corporation HER-2/neu fusion proteins
GB9930359D0 (en) * 1999-12-22 2000-02-09 Glaxo Group Ltd Novel polypeptides
GB0027088D0 (en) 2000-11-06 2000-12-20 Glaxo Group Ltd DNA expression vectors
ATE346947T1 (de) 2000-07-21 2006-12-15 Glaxo Group Ltd Kodon-optimierte papillomavirussequenzen
EP1478371A4 (en) * 2001-10-12 2007-11-07 Univ Iowa Res Found METHOD AND PRODUCTS FOR IMPROVING IMMUNE RESPONSES WITH IMIDAZOCHINOLINE COMPOUNDS
GB0212046D0 (en) 2002-05-24 2002-07-03 Glaxo Group Ltd Vaccines
DK1511768T3 (da) 2002-06-11 2007-08-20 Glaxosmithkline Biolog Sa Immunogene sammensætninger

Also Published As

Publication number Publication date
JP2007505827A (ja) 2007-03-15
CA2538197A1 (en) 2005-03-24
ZA200602156B (en) 2007-07-25
WO2005025614A2 (en) 2005-03-24
US20080145375A1 (en) 2008-06-19
IL174131A0 (en) 2006-08-01
KR20070029111A (ko) 2007-03-13
RU2370537C2 (ru) 2009-10-20
NZ545948A (en) 2009-07-31
AU2004271726A1 (en) 2005-03-24
WO2005025614A3 (en) 2005-10-06
SG145767A1 (en) 2008-09-29
MXPA06002969A (es) 2007-03-26
MA28323A1 (fr) 2006-12-01
BRPI0414381A (pt) 2006-11-21
GB0321615D0 (en) 2003-10-15
RU2006106848A (ru) 2007-10-27
NO20061242L (no) 2006-06-01
CN1878567A (zh) 2006-12-13
EP1682175A2 (en) 2006-07-26

Similar Documents

Publication Publication Date Title
ATE363383T1 (de) Schlingenware
DE502004011955D1 (de) Doppelkuppllungsgetriebe
DE502004001683D1 (de) Kabelführung
IS8387A (is) Ónæmisvaldandi samsetningar
DE60319796D1 (de) tsdetektion
DE602004008426D1 (de) Airbagfaltverfahren
FR2862675B1 (fr) Defonceuse
DE602004000258D1 (de) Einhebelwasserarmatur
DE602004014685D1 (de) Heizvorrichtung
DE602004013661D1 (de) Spritzgiessnadelverschlussbuchse
DE502004002978D1 (de) N-biarylamide
DE602004009212D1 (de) Fluidstrahlbohrwerkzeug
DE602004009257D1 (de) Bremsschlauchanordung
DE602004010064D1 (de) Freilaufkupplungsfeder
IS2922B (is) Bóluefni
DE602004025937D1 (de) 2-aminobenzoylderivate
DE50305802D1 (de) Stanz-prägeniet
FR2864125B1 (fr) Caillebotis
DE602004008040D1 (de) Natrium-kobaltoxid-hydrat
DE502004007959D1 (de) Prolinylarylacetamide
DE20317661U1 (de) Faltkleiderschrank
DE602004029759D1 (de) Wälzkörperschraubvorrichtung
DE502004012392D1 (de) Wischarmgelenkvorrichtung
FI6598U1 (fi) Kantopoimuri
FR2861254B1 (fr) Ecuelle